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 1 
Abstract 
 Providing women with safe and effective means of contraception is important when 
assessing women’s health needs. Women with HIV can spread the disease to their baby 
through vertical transmission but this may be curtailed by the use of antiretroviral therapy. 
Additionally, providing women who have HIV with safe contraception options improves 
women’s overall health. However, there is concern that some hormonal contraceptives may 
affect the metabolism with certain antiretrovirals. A literature search was conducted using 
the databases Medline, PubMed, and Global Health. Articles meeting the inclusion criteria 
were then assessed. Thirteen peer-reviewed articles were identified. Several studies 
indicated that there were no relevant interactions for measures of disease progression, 
disease transmission and tolerability. However, some articles suggested that there were 
safer means of contraception that should be made available to women on antiretroviral 
therapy. Efavirenz was shown to induce adverse contraception efficacy when co-
administered. Collectively, hormonal contraception is widely safe for women using 
antiretroviral therapy. HIV positive women should be educated on the risks associated with 
hormonal contraception as well as be provided with options that fit their reproductive 
health needs.  
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Introduction/ Purpose of the Study 
 Human Immunodeficiency Virus, commonly known as HIV, is a global epidemic, 
effecting over 36.7 million worldwide (WHO 2017). HIV can affect both women and men 
alike, additionally there is also risk for vertical transmission from mother to baby, 
especially in developing countries (Malunguza, Hove-Musekwa, & Mukandavire, 2017). 
Developing countries have limited access to perinatal and antiretroviral care, which may 
explain higher rates of vertical transmission (Malunguza et al., 2017). Although there has 
been a decline in death and birth rates due to HIV, many countries, such as those in sub-
Saharan African are expecting exponential population growth within the next 30 years. 
With this increase in population, more people may be affected by HIV/AIDS than ever 
before. AIDS education exists in many of these countries, however, there is a lack of 
attention in maternal health services (Malunguza et al., 2017). With the global burden of 
HIV in these countries being the highest around the world, there is a desperate need for 
increased women’s health services (WHO, 2017).  Unintended pregnancies among HIV- 
positive women may have consequences for maternal morbidity and vertical transmission 
(Patel et al., 2015). Researchers explain that the most important component of good 
contraception in public health is the availability of choices (Stringer et al., 2007). 
Additionally, the use of contraceptives can decrease the prevalence of maternal morbidity 
and mortality (Tittle, Bull, Boffito, & Nwokolo, 2015). Women with HIV often use separate 
medications to prevent disease progression (antiretroviral therapy) and disease 
transmission (birth control).  Almost 50% of those diagnosed with HIV use some form of 
antiretroviral therapy (WHO 2017). Additionally, the WHO states that up to 77% of women 
who are HIV-positive engage in ART (WHO 2017).  Since the use of antiretroviral therapy is 
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increasing worldwide, assessing the impact of its use with hormonal contraceptives will be 
beneficial when addressing disease transmissibility of HIV-positive women on therapy 
(Kourtis et al., 2017).  
It is important to examine the concurrent use of hormonal contraceptives for birth 
control, and antiretroviral therapy in women with HIV (Malunguza et al., 2017).  There has 
been some concern with the efficacy of hormonal contraceptives and antiretroviral therapy 
when co-administered.   Some pharmacokinetic data suggests potential interactions 
between the two medications (Kourtis et al., 2017). These interactions are a key concern 
for public health officials in regards to HIV, as disease transmission and progression are 
key concerns. Because antiretroviral therapy and hormonal contraceptives have common 
metabolic pathways, the blood levels of both hormonal contraceptives and antiretrovirals 
may be affected by their concurrent use (Landolt et al., 2013). Interactions between these 
drugs could potentially lead to decreased contraceptive effectiveness, therefore increasing 
the change of vertical transmission. Additionally, a decrease in ART effectiveness could lead 
to increased disease progression and horizontal transmission (Nanda et al., 2017). 
Enhanced toxicity is also a concern when assessing the relationships between these drugs 
(Landolt et al., 2013).  It is important to provide women living with HIV with safe and 
effective contraception to prevent unintended pregnancy and decrease the incidence of 
maternal-to-child HIV-1 transmission (Day et al., 2014). Few studies examining the 
relationship between hormonal contraceptives and antiretrovirals have been conducted 
and studies have shown conflicting results (Landolt et al., 2013). Studies of interactions 
have been limited by short follow up times, inconclusive end points, small sample sizes and 
uninfected populations (Pyra et al., 2015). Since data in the field is limited, contraception 
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options for HIV-positive women receiving antiretroviral therapy is also limited (Watts et 
al., 2008). The primary purpose of this study is to provide a systematic review of research 
articles to determine the potential effects on hormonal efficacy and disease progression 
from concurrent use of hormonal contraceptives and antiretroviral therapy in HIV-positive 
women. 
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Literature Review 
In 2015, there were over 36.7 million people living with HIV (WHO, 2016). 
Additionally, sub-Saharan Africa bears the greatest global burden of HIV/AIDS, which 
account for 70% of all HIV infections. Nearly 13 million women in Sub-Saharan Africa live 
with AIDS (Patel et al., 2015). HIV is spread through certain bodily fluids, such as breast 
milk, blood, semen, and vaginal secretions (CDC 2016).  HIV targets the body’s immune 
system, more specifically CD4+ cells (CDC 2016).  Although there is no cure for HIV, it can 
be managed with the use of Antiretroviral therapy (ART). ART was introduced in the mid-
1990s, and those who are infected have greater chances to live longer lives, and decrease 
the odds of transmission to others.  Because no cure currently exists for HIV, prevention 
and decreasing the transmission of the disease is a concern among health professionals.  
The proportion of HIV and AIDS cases among women continues to grow world-wide, 
with women accounting for over half of HIV-infected adults (Luque et al., 2015). Over 
ninety percent of the HIV positive women in sub-Saharan Africa are between 15 and 49 
years of age (Day et al., 2014). Because these woman can be considered as being in child 
bearing age, it is important to address the reproductive needs of women living with the 
disease. Condom use is highly recommended for HIV-infected women, but this form of 
contraception is not always reliable or accessible, so therefore healthcare professionals 
encourage women to use additional forms of contraception (Leticee, Viard, Yamgnane, 
Karmochkine, & Benachi, 2012). Additionally, the availability of contraception among HIV-
Infected women who desire to have it has been a key strategy in preventing pediatric AIDS, 
(Stringer et al., 2007).  
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Hormonal contraceptives are steroid hormones that serves as birth control (Nanda 
et al., 2017). Hormonal contraceptives, most of which contain some form of progestin, a 
synthetic progestogen that mimics progesterone alone or combined with estrogen, are 
widely used by women all over the globe, to prevent pregnancy and/or to alleviate 
hormonal imbalances (CDC 2016, Luque et al., 2015).  Globally, hormonal contraceptives 
are the most widely used contraception method among women (Kourtis et al., 2017). 
Women in developing countries experience a high prevalence HIV (more than 95% of HIV 
infections are in developing countries), and these women tend to use contraceptive 
methods such as depot medroxyprogesterone (DMPA), a hormonal contraceptive (WHO 
2016, Luque et al., 2015).  Hormonal contraceptives are metabolized via cytochrome P450 
enzyme system in the liver, especially via CYP3A4 (Kancheva Landolt et al., 2016). The 
metabolism of hormonal contraceptives allows the drug to be broken down by the body 
and to carry out its hormonal purpose (Landolt et al., 2013). Globally, 14% of women use 
hormonal contraception (Mitchell, 2004). A study conducted by Nieves and associates 
concluded that 54% of women used a form of hormonal contraception as a means of birth 
control for heterosexual couples (Nieves et al., 2015).  
Treatment of HIV through antiretroviral therapy usually contains a combination of 
drugs, which target different stages of the HIV lifecycle (Tittle et al., 2015). Antiretroviral 
therapy has been shown to both increase and decrease the efficacy of hormonal 
contraception, depending on the drug it is administered with, however findings continue to 
be mixed in nature (Luque et al., 2015).  There are six main classes of antiretroviral drugs 
(Sharma & Walmsley, 2015). The classes of antiretroviral therapy include: nucleoside 
reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors 
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(NNRTIs), Protease Inhibitors (PI), Integrase Inhibitors (INI), Entry Inhibitors (Sharma & 
Walmsley, 2015). All of these drugs target the HIV lifecycle in different ways. Usually, two 
or three of these drug classes are combined to decrease the progression of HIV (Sharma & 
Walmsley, 2015). Generally, most people start HIV treatment with two NRTI drugs, along 
with either one NNRTI or one PI and one INI (Nanda et al., 2017).  Although NRTIs and INI 
are not generally inducers of the cytochrome P450 system, PIs and NNRTIs are 
metabolized by enzymes found in the cytochrome P450 system (Nanda et al., 2017) and 
may specifically inhibit cytochrome 3A4, however findings continue to be mixed in nature 
(Atrio et al., 2015). 
Some antiretrovirals (ARVs), particularly Nevirapine and Efavirenz, are 
metabolically synthesized via the cytochrome P450 enzyme system (Kancheva Landolt et 
al., 2016).  Since some protease inhibitors can inhibit enzyme systems like CYP3A4, the 
bioavailability of drugs that use the same enzyme systems, like hormonal contraceptives, 
may decrease (Atrio et al., 2015). Additionally, some studies suggest that CYP3A4 activity 
differs by gender, and suggest that women have 40% higher CYP3A4 activity than men 
(Luque et al., 2015).  With increased activity of this enzyme, which aids in breaking down 
hormonal contraception in women, examining the relationship between these drugs is key, 
so that women with HIV have options that meet reproductive health needs.  
Efavirenz is usually a first-line treatment for HIV, followed by nevirapine, which are 
both NNRTIs (Scarsi et al., 2016). Landlot and associates found that efavirenz, in contrast to 
nevirapine, when co-administered with combined oral contraceptives, is associated with 
unfavorable progesterone and antiretroviral levels (Landolt et al., 2013). Patel and 
associates documented a similar finding; efavirenz, compared to nevirapine experienced 
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higher rates of pregnancy among those using DMPA and hormonal contraceptives (Patel et 
al., 2015). Both studies note that the failure of contraceptives was minimal and was no 
statistically significant different than the general population.  
Effects on Contraception 
Hormonal contraceptives are known to thicken the mucus of the cervix, so that 
sperm cannot reach the egg (Atrio et al., 2015). Suppressed ovulation is a key determinate 
in judging the efficacy of hormonal contraceptives (Luque et al., 2015). Researchers did not 
observe any pregnancies concluding that DMPA is a safe and tolerable amongst women 
using antiretroviral therapy (Luque et al., 2015).  
Pyra and associates suggest that both oral contraceptives and implants are effective 
in reducing pregnancy when co-administered with antiretroviral therapy (Pyra et al., 
2015). Although researchers found that antiretroviral therapy did not significantly 
diminish the effectiveness of contraception, there was a non-statistically significant 
reduced effectiveness when co-administered with the antiretroviral, efavirenz (Pyra et al., 
2015). Implants (IUDs) were the most protective contraceptive method for women 
engaging in ART (Pyra et al., 2015).   
Atrio and associates found that women taking protease inhibitors demonstrated 
thickened cervical mucus similar to those not on antiretroviral therapy (Atrio et al., 2015).  
Thickened cervical mucus serves as a barrier to sperm penetration (Atrio et al., 2015). The 
findings of the research suggested contraceptive (pill) efficacy in HIV positive women 
taking antiretroviral therapy that includes protease inhibitors, is an appropriate method of 
birth control for HIV positive women (Atrio et al., 2015).   
Effects on Disease Transmission and Progression 
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Stringer and associates concluded that women who used hormonal methods were 
more likely to become pregnant, as compared to the IUD (Stringer et al., 2007). Also, 
women who use hormonal contraception may experience disease progression more 
commonly than those using the IUD (Stringer et al., 2007).  Research suggests the IUD may 
be a safer and more effective option than hormonal contraception in HIV+ women, in 
regards to disease progression (Stringer et al., 2007). However, these results are not 
consistent.  
Using blood measures to assess CD4+ cell counts, Whitman and associates found 
that there was no statistically significant increase in disease progression among those that 
used hormonal contraception, including DMPA and the pill, as compared to those that used 
non-hormonal methods such as the IUD or condoms, (Whiteman et al., 2016). Additionally, 
those engaging in antiretroviral therapy saw no statistically significant difference in mean 
changes of CD4+ cell counts when comparing those that used hormonal methods to those 
that did not (Whiteman et al., 2016).  The researchers concluded that hormonal 
contraception was not significantly associated with HIV disease progression or 
antiretroviral effectiveness among women with HIV (Whiteman et al., 2016).  
Another study assessing DMPA’s effect on HIV antiretroviral drugs evaluated the 
safety and tolerability of co-administration (Watts et al., 2008). Tolerability was measured 
by the instances of adverse side effects (Watts et al., 2008). Researchers assed DMPA use 
with various antiretroviral drugs including nelfinavir, efavirenz, and nevirapine (Watts et 
al., 2008). Although some participants experienced adverse side effects including vaginal 
bleeding, headache, abdominal pain, mood changes, and other symptoms, researchers 
attributed these findings to the general side effects of DMPA that could occur in all women 
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regardless of HIV status (Watts et al., 2008).  The study found that there were no significant 
changes in CD4+ cell count or HIV RNA levels with the use of DMPA (Watts et al., 2008). 
This suggested that co-administration of hormonal contraceptives and antiretrovirals is 
safe among HIV-positive women. 
Use of DMPA In a similar study, researchers investigated DMPA and antiretroviral 
use and compared plasma and genital HIV-1 RNA shedding (Day et al., 2014). Researchers 
found that DMPA expose did not increase detection of plasma nor cervical HIV-1 RNA (Day 
et al., 2014). Day and associates concluded that administration of DMPA among HIV-
infected women is a safe option for those currently engaging in ART therapy.  
Effects on Pharmacokinetics 
Kancheva and associates suggest that there are no relevant interactions between 
hormonal contraceptives and antiretrovirals. However, The researchers observed that 
there was a high variability in estrogen levels of the participants (Landolt et al., 2013). This 
may warrant concern, as there could potentially be an issue in estrogen breakdown among 
participants. The study found no clinically relevant interactions between DMPA and the 
antiretroviral drugs lopinavir and a low dose ritonavir among HIV-positive women, 
compared to those that are HIV-positive, but are not receiving antiretroviral therapy. Both 
lopinavir and ritonavir are both protease inhibitors (Luque et al., 2015). There was no 
significant difference in hormonal levels of either contraceptive in blood samples between 
the two groups.  
 Some research has shown that certain classes of antiretroviral therapy, such as PIs   
and NNRTIs can inhibit hepatic enzymes such as cytochrome 3A4, however findings 
continue to be mixed in nature (Atrio et al., 2015).  
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Methods 
The process of the systematic review started with the research question, “Does the 
use of antiretroviral therapy or hormonal contraceptives alter the efficacy of either drug 
when used concurrently in HIV-positive women?” Hormonal contraceptives in this study 
include birth control pills and the DMPA shot. The systematic review search was conducted 
through Georgia State University’s library website using the following databases: Global 
Health, Medline, and PubMed. Based on the purpose of this study keywords such as: 
hormonal contraceptives, contraception, antiretroviral therapy, disease 
transmission/progression and ART were used to conduct the search. The search criteria 
included: ((hormonal contraception) OR (contraceptive)) AND ((antiretroviral) OR (art)).  
After this search was conducted the search criteria was again searched using disease 
transmission/progression. The search criteria included: ((hormonal contraception) OR 
(contraceptive)) AND ((antiretroviral) OR (art)) AND ((disease progression) or (disease 
transmission)). The results from both searches were combined as the results of the second 
search were yielded in the initial search. All articles from the systematic review were 
chosen from these databases. The flowchart (Figure 1) details the process of the systematic 
review and how the final articles were chosen. The primary goal for the systematic review 
was whether co-administration of hormonal contraceptives and antiretroviral therapy had 
an effect on efficacy of either drug. The secondary goals were to assess whether co-
administration played a role in disease progression and pregnancy acquisition.  The 
inclusion criteria for the systematic review consisted of randomized and nonrandomized 
studies, including randomized control trials and cohort studies. Also, all studies included 
the systematic review co-administered both antiretroviral therapy and hormonal 
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contraception. The inclusion criteria are detailed in Table 1. Only articles that assessed 
HIV-positive women were included. English language articles included the systematic 
review were published between the following dates: January 2007-March 2017. There 
were no restrictions based on age, country, or type of antiretroviral therapy used. After 
eliminating articles that did not fit the inclusion criteria, remaining articles were reviewed 
based on the research questions and the availability of full text articles. After assessing the 
articles that met all of the inclusion criteria, the final literature for the systematic review 
was chosen. Finally, a quality assessment was conducted on eligible articles based on the 
following criteria: study design, purpose clearly stated, use of antiretroviral therapy, use of 
hormonal birth control (pill/ DMPA) stated, conclusions appropriate per results. The 
quality assessment is detailed in Table 2.  
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Figure 1. Flowchart of Selection of Studies 
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Table 1. Inclusion and Exclusion Criteria 
 
Inclusion Criteria Exclusion Criteria 
• Articles using both hormonal 
contraceptives and antiretroviral 
therapy within the study 
• Cohort Studies 
• Randomized/Non-randomized 
Control Trials 
• Female Subjects 
• Full text English Articles  
• Articles published between January 
2007- March 2017 
• Articles with primary outcomes of 
efficacy, disease progression, or 
pregnancy incidence (ovulation) 
 
• Systematic Reviews 
• Articles not in English 
• Studies without full text available 
after search 
• Case Control Studies 
• Studies including nonhuman subjects 
• Secondary Analysis 
• Articles with behavioral outcomes 
(for the interest of this study, 
behavioral outcomes were excluded 
due to the initial purpose being drug 
efficacy) 
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Table 2. Quality Assessment of Reviewed Articles 
 
Author Purpose 
Clearly 
Stated 
Use of 
Antiretroviral 
Use of 
hormonal 
Contraception 
(Pill/DMPA) 
Conclusions 
Appropriate 
per Results 
Study 
Design 
Atrio 
(2015) 
Yes Yes Yes Yes Non-
Randomized 
Clinical Trial 
Day 
(2015) 
Yes Yes Yes Yes Prospective 
Cohort Study 
Kancheva 
Landlot 
(2016) 
Yes Yes Yes Yes Non-
randomized 
Clinical Trial 
Landlot 
(2013) 
Yes Yes Yes Yes Non-
randomized 
Clinical Trial 
Luque 
(2015) 
Yes Yes Yes Yes Non-
Randomized 
Clinical Trial 
Nanda 
(2008) 
Yes Yes Yes Yes Non-
Randomized 
Clinical Trial 
Nanda 
(2013) 
Yes Yes Yes Yes Non-
Randomized 
Clinical Trial 
Patel 
(2015) 
Yes Yes Yes Yes Retrospective 
Cohort Study 
Polis 
(2012) 
Yes Yes Yes Yes Prospective 
Cohort Study 
Pyra 
(2015) 
Yes Yes Yes Yes Retrospective 
Cohort Study 
Stuart 
(2011) 
Yes Yes Yes Yes Prospective 
Cohort Study 
Watts 
(2008) 
Yes Yes Yes Yes Non-
Randomized 
Clinical Trial 
Whiteman 
(2016) 
Yes Yes Yes Yes Prospective 
Cohort Study 
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Results 
 
Georgia State University’s Library website provides 21 A-Z databases for student 
use. The databases most appropriate for this systematic review were PubMed, Medline, and 
Global Health. PubMed is maintained by the National Center for Biotechnology Information 
(NCBI) at the US National Library of Medicine (NLM) and provides biomedical literature 
from MEDLINE, life science journals, and online books in the fields of life sciences, 
behavioral sciences, chemical sciences and bioengineering. Using the keywords ((hormonal 
contraception) OR (contraceptive)) AND ((antiretroviral) OR (art)), and ((hormonal 
contraception) OR (contraceptive)) AND ((antiretroviral) OR (art)) AND ((disease 
progression) or (disease transmission)), PubMed yielded 617 citations. The articles were 
filtered to show only full text articles, which yielded 506 citations. The titles of the articles 
and the abstracts were reviewed for relevance, 24 articles were identified and 9 articles 
met the inclusion criteria.  
Global Health is a public health database that provides information in international 
health, biomedical life sciences, public health nutrition, non-communicable diseases and 
more. The same keyword search was used for Global Health as PubMed.  Global Health 
yielded 227 citations. The titles of the citations were evaluated as well as the abstracts for 
relevancy. There were 21 articles reviewed and 3 met the inclusion criteria for the 
systematic review. 
 The Medline database combines the National Library of Medicine’s database 
with links to full text articles. The Medline database provides information from leading 
medical journals on information relating to medicine, dentistry, the healthcare system, 
preclinical sciences, and veterinary medicine. The keyword search yielded 325 citations. 
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The titles of the articles were evaluated as well as abstracts for relevancy. There were 27 
articles reviewed and only one met the inclusion criteria for the systematic review. Most of 
the articles that met the inclusion criteria were provided on at least two of the databases. It 
is also important to note that all of the articles identified for the secondary outcomes, such 
as disease transmission were included in the above keyword search. All of the articles 
identified in the systematic review met all inclusion criteria and the outcomes were 
relevant to the study. Also, there were additional articles that could have been considered 
for the systematic review, but these databases were not available through the Georgia State 
University Library system.  
Table 3 details the characteristics of the studies included in the systematic review. 
The studies in the systematic review varied in setting, however, all of the studies were 
published from 2007-2017.  6 (46%) of the studies were conducted in African countries. Of 
the 13 articles that met the inclusion criteria, one study (7.7%) had outcomes that found 
increased disease progression. 6 studies (46%) of the studies had outcomes that monitored 
ovulation, cervical mucus, or pregnancy rates. Four studies (31%) assessed the 
pharmacokinetics of co-administration of antiretroviral therapy and hormonal 
contraception. One study detailed virological failure rates, (defined as failure to achieve 
virologic suppression, switch to second line therapy, or death within 12 months of ART 
initiation), of antiretroviral therapy (7.7%) when co-administered with hormonal 
contraception. Also, there was one study that detailed HIV-1 cervical shedding. 
 All of the studies had a clearly stated purpose and co-administration of 
antiretroviral therapy and hormonal contraception (combined oral contraceptives, 
progesterone only, and/or injectable), and the conclusions were appropriate per the 
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results. Additionally, 11 of the studies reported a statistical significance of the results 
(Table 4), while two study reported pharmacokinetic results in graphic form. Of the 13 
studies reviewed, 10 studies found no relevant interactions between co-administration of 
the drugs. Whitman and Associates conducted a study detailing disease transmission found 
no relevant interactions between co-administration (Whiteman et al., 2016). However, Day 
and associates found an increased risk of diseases transmission among women receiving 
DMPA and antiretroviral therapy (Day et al., 2014). 
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Table 3. Characteristics of Studies Included in the Systematic Review 
 
Author Title Study 
Design 
Sample 
Populatio
n & 
Setting 
Intervention Outcome 
(Atrio et 
al., 
2015) 
The effect 
of 
protease 
inhibitors 
on the 
cervical 
mucus of 
HIV-
positive 
women 
taking 
norethind
rone 
contracep
tion 
Non-
Randomi
zed 
Clinical 
Trial 
43 HIV+ 
women 
18-44/ 
California 
16 women were 
given protease 
inhibitors (ART) 
and 
Norethindrone(pro
gesterone only 
pills),  
17 women were 
controls, given only 
Norethindrone pills 
No difference in 
cervical mucus score 
between HIV+ 
women taking PI 
and those not taking 
PI 
(Day et 
al., 
2014) 
A 
Prospecti
ve Cohort 
Study of 
the Effect 
of Depot 
Medroxyp
rogestero
ne 
Acetate 
on 
Detection 
of Plasma 
and 
Cervical 
HIV-1 in 
Women 
Initiating 
and 
Continuin
g 
Antiretro
viral 
Therapy: 
Prospect
ive 
Cohort 
Study 
102 HIV 
positive 
women in 
Kenya 
under ART  
Women on ART 
therapy were 
administered 
DMPA or received 
no DMPA 
Results suggest that 
DMPA is unlikely to 
increase infectivity in 
HIV-positive women 
who are adherent to 
effective ART 
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(Kanche
va 
Landolt 
et al., 
2016) 
 
High 
variability 
of 
hormonal 
levels and 
no 
clinically 
relevant 
interactio
n 
between 
ethinyl 
estradiol, 
desogestr
el and 
lopinavir/
ritonavir 
in a small 
sample of 
HIV-
positive 
adolescen
ts: 
Non-
randomi
zed 
Clinical 
Trial 
18 HIV+ 
women in 
Bangkok 
and 
Thailand 
All women were 
administered 
ethinyl 
estradiol/desogestr
el (combined oral 
contraceptives) 
and 
Lopinavir/ritonavir 
(ART)  
No clinically 
relevant interaction 
between combined 
oral contraceptives 
and antiretroviral 
therapy 
(Landolt 
et al., 
2013) 
 
Efavirenz, 
in 
Contrast 
to 
Nevirapin
e, is 
Associate
d With 
Unfavora
ble 
Progester
one and 
Antiretro
viral 
Levels 
When 
Coadmini
stered 
With 
Combined 
Oral 
Contracep
Non-
randomi
zed 
Clinical 
Trial 
34 Thai 
HIV+ 
women  
16 women were 
administered 
Efavirenz and 
desogestrel/ethinyl 
estradiol 
(Combined Oral 
Contraceptives), 18 
women were 
administered 
Nevirapine and 
desogestrel/ethinyl 
estradiol 
Coadministration of 
Efavirenz and COCs 
is associated with 
unfavorable 
progesterone and 
antiretroviral levels 
compared to 
Nevirapine.  
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tives: 
(Luque 
et al., 
2015) 
Depot 
Medroxyp
rogestero
ne 
Acetate in 
Combinat
ion with a 
Twice-
Daily 
Lopinavir
-
Ritonavir-
Based 
Regimen 
in HIV-
Infected 
Women 
Showed 
Effective 
Contracep
tion and a 
Lack of 
Clinically 
Significan
t 
Interactio
ns, with 
Good 
Safety 
and 
Tolerabili
ty: 
Results of 
the ACTG 
5283 
Study 
Non-
Randomi
zed 
Clinical 
Trial 
48 HIV+ 
women 
from 5 
AIDS 
Clinical 
Trial 
Group 
clinical 
research 
sites 
(CRSs) and 
8 National 
Institute of 
Child 
Health and 
Human 
Developm
ent 
(NICHD)-
funded 
IMPAACT 
CRSs 
The intervention 
group received 
DMPA and 
lopinavir/ritonavir, 
the control group 
received DMPA 
while no 
antiretroviral 
therapy.  
No changes in 
lopinavir and 
ritonavir levels after 
DMPA initiation. 
DMPA was well 
tolerated and there 
was a suppression of 
ovulation.   
(Nanda 
et al., 
2008) 
Pharmaco
kinetic 
interactio
ns 
between 
depot 
medroxyp
rogestero
Non-
Randomi
zed 
Clinical 
Trial 
30 HIV+ 
women  
15 using ART ( 
Efavirenz, 
zidovudine, 
lamivudine) 
receiving DMPA 
shots, and 15 non 
ART therapy users 
receiving DMPA 
Pharmacokinetic 
interactions were 
similar in those 
engaging in ART and 
those who did not 
receive ART therapy. 
Suggesting no 
interference with 
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ne acetate 
and 
combinati
on 
antiretrov
iral 
therapy 
shots 
 
 
contraceptive 
effectiveness.  
 (Nanda 
et al., 
2013) 
Nevirapin
e-based 
antiretrov
iral 
therapy 
does not 
reduce 
oral 
contracep
tive 
effectiven
ess: 
Non-
Randomi
zed 
Clinical 
Trial 
302 
women in 
South 
Africa and 
Uganda 
196 women 
received 
Nevirapine (ART) 
and Combined Oral 
Contraceptives, 
206 women 
received Combined 
Oral Contraceptives 
and no ART 
Use of ART did not 
affect the risk of 
pregnancy or 
ovulation, 
suggesting 
Nevirapine-based 
ART does not effect 
combined oral 
contraceptive 
effectiveness.  
(Patel et 
al., 
2015) 
Pregnanc
y rates in 
HIV-
positive 
women 
using 
contracep
tives and 
efavirenz-
based or 
nevirapin
e-based 
antiretrov
iral 
therapy in 
Kenya: a 
retrospec
tive 
cohort 
study 
Retrospe
ctive 
Cohort 
Study 
24,560 
HIV 
positive 
women 
enrolled in 
HIV health 
facilities in 
western 
Kenya 
For birth control, 
women used either: 
DMPA, Combined 
Oral Contraceptives 
or Implants 
 
For ART regimens, 
women used either: 
Nevirapine-based 
ART, Efavirenz-
based ART 
lopinavir/ritonavir 
based ART or no 
ART 
Implant use was the 
most protective 
against pregnancy, 
regardless of ART 
use.  
 
Those using 
hormonal 
contraceptives 
(DMPA and COCs) 
saw higher 
incidences of 
pregnancy than 
those using 
implants. 
 
Those taking 
Efavirenz-based 
ART therapy saw the 
highest incidence of 
pregnancy.  
 
(Polis et 
al., 
2012) 
Effect of 
injectable 
contracep
tive use 
Prospect
ive 
Cohort 
Study 
418 HIV- 
positive 
Ugandan 
Women  
ART and hormonal 
contraceptive use 
(DMPA) levels 
were use measured 
Virologic failure 
rates while 
administered with 
DMPA at 12 months 
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on 
response 
to 
antiretrov
iral 
therapy 
among 
women in 
Rakai, 
Uganda 
at baseline and 12 
months after the 
start of the study 
among women who 
used both drugs   
were similar to 
those virologic 
failure rates at 
baseline. 
 
No deleterious effect 
of DMPA use on 
response to ART  
 
Injectable 
contraception was 
not associated with 
an increased risk of 
ART failure 
 
 
(Pyra et 
al., 
2015) 
Effectiven
ess of 
hormonal 
contracep
tion in 
HIV-
infected 
women 
using 
antiretrov
iral 
therapy: 
Retrospe
ctive 
Cohort 
Study 
5153 HIV-
positive 
women 
followed 
in HIV 
prevention 
studies in 
Africa 
Women using ART 
used a variety of 
ART 
regimens(Nevirapi
ne and Efavirenz 
were the most 
common) and used 
the following types 
of birth control: 
COCs, Injectables, 
Implants, None 
Hormonal 
contraceptives are 
highly effective in 
reducing pregnancy 
risk in HIV-positive 
women currently 
using ART 
(Stuart 
et al., 
2011)  
Combined 
Oral 
Contracep
tives and 
Antiretro
viral 
PK/PD in 
Malawian 
Women: 
Pharmaco
kinetics 
and 
Pharmaco
dynamics 
of a 
Combined 
Oral 
Prospect
ive 
Cohort 
Study 
9 Malawi 
Women 
who were 
HIV+ and 
taking 
ART, HIV+ 
women 
not taking 
ART and 
HIV 
negative 
women 
All women, among 
the three groups 
were given 
hormonal 
contraceptives  
Combined oral 
contraceptives 
maintained 
effectiveness 
regardless of ART 
use.  
 
Hormonal levels 
were higher in HIV-
positive women 
than in HIV-negative 
women, which 
debunk the notion 
that COCs are less 
effective when co-
administered with 
ART like 
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Contracep
tive and a 
Generic 
Combined 
Formulati
on 
Antiretro
viral in 
Malawi: 
(Nevirapine).  
(Watts 
et al., 
2008) 
Safety 
and 
tolerabilit
y of depot 
medroxyp
rogestero
ne acetate 
among 
HIV-
infected 
women 
on 
antiretrov
iral 
therapy: 
ACTG 
A5093 
Non-
Randomi
zed 
Clinical 
Trial 
56 HIV-
positive 
women 
 
16 HIV-
negative 
women   
HIV-infected 
women on selected 
ARV regimens or 
no ARV were 
administered 
DMPA 150 mg 
intramuscularly 
and evaluated for 
12 weeks for 
adverse events, 
changes in CD4+ 
count and HIV RNA 
levels, and 
ovulation. 
DMPA 
administration in 
HIV-infected women 
on ART regimens is 
similar to 
observations in HIV-
negative women.  
 
DMPA prevented 
ovulation and did 
not affect CD4+ 
counts or HIV RNA 
levels 
(White
man et 
al., 
2016) 
Associatio
ns of 
hormonal 
contracep
tive use 
with 
measures 
of HIV 
disease 
progressi
on and 
antiretrov
iral 
therapy 
effectiven
ess 
Prospect
ive 
Cohort 
Study 
709 HIV-
positive 
women in 
Russia 
Women either used 
ART or No ART 
Therapy while 
assigned to the 
following 
contraception 
methods: COCs, 
DMPA, Non-
hormonal methods 
No significant 
association between 
use of hormonal 
contraception and 
disease 
transmission or ART 
effectiveness among 
HIV-positive women 
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Table 4.  Detailed Results of Reviewed Articles 
 
 
Author Title Intervention Statistical Results 
(Atrio et 
al., 
2015) 
The effect 
of 
protease 
inhibitors 
on the 
cervical 
mucus of 
HIV-
positive 
women 
taking 
norethind
rone 
contracep
tion 
Women in the 
intervention group were 
given protease inhibitor 
regimens, while the 
control group received 
no ART treatment. 
 
Women were 
administered 
norethindrone 0.35 mg 
contraception for 21 
days.  
Baseline Cervical Mucus Score (CMS) was 
similar to baseline (p>.01) 
 
CMS score after 21 days among those taking PI= 
3.5 
 
CMS score after 21 days among the control=4 
 
(P-value> 0.28) 
 
(Day et 
al., 
2014) 
A 
Prospecti
ve Cohort 
Study of 
the Effect 
of Depot 
Medroxyp
rogestero
ne 
Acetate 
on 
Detection 
of Plasma 
and 
Cervical 
HIV-1 in 
Women 
Initiating 
and 
Continuin
g 
Antiretro
viral 
Therapy: 
The standard ART 
regimen was: zidovudine 
or stavudine, 
lamivudine, and 
nevirapine 
 
Exposure to hormonal 
contraception was 
defined as reported use 
within the past 70 days.  
 
The comparison group 
was women not using 
hormonal contraception, 
which included no 
contraception, condoms 
only, hysterectomy or 
tubal ligation.  
 
Compared to visits with no hormonal 
contraception exposure, DMPA exposure did not 
increase detection of plasma (adjusted odds 
ratio (AOR) 0.81, 95% CI 0.47–1.39) or cervical 
HIV-1 RNA (AOR 1.41, 95% CI 0.54–3.67) 
 
(Kanche
va 
High 
variability 
HIV-positive females on 
Lopinavir/ritonavir-
Geometric mean ratios (GMR) of Ctrough (LPV/r 
concentration) in HIV-positive women on LPV/r 
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Landolt 
et al., 
2016) 
 
of 
hormonal 
levels and 
no 
clinically 
relevant 
interactio
n 
between 
ethinyl 
estradiol, 
desogestr
el and 
lopinavir/
ritonavir 
in a small 
sample of 
HIV-
positive 
adolescen
ts: 
based regimen (LPV/r) 
were administered COC 
tablets, containing 0.030 
mg ethinyl 
estradiol/0.150 mg 
desogestrel for 2 
consecutive cycles, 
starting between the 
first and the third day of 
the cycle. (56 study days: 
21 days hormonal 
tablets—7 days, 
repeated)  
 
HIV negative controls 
were administered the 
COC tablets, containing 
0.030 mg ethinyl 
estradiol/0.150 mg 
desogestrel for 2 
consecutive cycles, 
starting between the 
first and the third day of 
the cycle. (56 study days: 
21 days hormonal 
tablets—7 days, 
repeated)  
  
with COC versus HIV-negative controls with COC 
only were 0.68 (95% CI: 0.42 to 1.08) or 32% 
decreased (P = 0.10) for EE2; and 1.08 (95% CI: 
0.73 to 1.60) or 8% increased (P = 0.68) for ENG 
(active metabolite in desogestrel). 
  
Ctrough of LPV decreased statistically 
insignificantly with COC and remained above the 
desired therapeutic minimum of 1.0 mg/L in all. 
(Landolt 
et al., 
2013) 
 
Efavirenz, 
in 
Contrast 
to 
Nevirapin
e, is 
Associate
d With 
Unfavora
ble 
Progester
one and 
Antiretro
viral 
Levels 
When 
Coadmini
Oral contraceptive (COC) 
containing 0.150 mg 
desogestrel /0.030 mg 
ethinyl estradiol with 
either nevirapine (NVP) 
or efavirenz (EFV) were 
administered to 34 HIV-
positive women.  
 
The targeted level for 
contraceptive 
effectiveness was 
endogenous 
progesterone level < 3.0 
ng/mL.  
 
The targeted levels for 
All subjects (18) in the NVP group had serum 
progesterone <1.0 ng/mL. Four of 16 subjects in 
the EFV group had serum progesterone >1.0 
ng/mL, including 3 subjects with >3.0 ng/mL 
(may indicate ovulation).  
 
The difference in progesterone levels between 
the 2 groups was statistically significant (P = 
0.04).  
 
The median C12 (concentration 12 hours after 
administration) of NVP increased insignificantly 
with COC. The median C12 of EFV decreased 
significantly (P = 0.02) by 22%. 3 of 16 subjects 
(19%) in the EFV group, C12 of EFV was below 
1.0 mg/L. 
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stered 
With 
Combined 
Oral 
Contracep
tives: 
antiretroviral therapy 
were >3.1 mg/L for NVP 
and 1.0-4.0 mg/L for 
EFV. 
(Luque 
et al., 
2015) 
Depot 
Medroxyp
rogestero
ne 
Acetate in 
Combinat
ion with a 
Twice-
Daily 
Lopinavir
-
Ritonavir-
Based 
Regimen 
in HIV-
Infected 
Women 
Showed 
Effective 
Contracep
tion and a 
Lack of 
Clinically 
Significan
t 
Interactio
ns, with 
Good 
Safety 
and 
Tolerabili
ty: 
Results of 
the ACTG 
5283 
Study 
24 HIV positive women 
receiving (10 Receiving 
Lopinavir 
(LPV)/Ritonavir (RTV) 
based therapy, 14 
receiving no therapy) 
 
All women received 
DMPA 
There were no changes in LPV or RTV exposure 
after DMPA. DMPA was well tolerated, and 
suppression of ovulation was maintained. 
 
(Nanda 
et al., 
2008) 
Pharmaco
kinetic 
interactio
15 HIV-positive women 
in the control group (not 
on ART) received a 
N/A 
 
The mean blood levels (area under curve) for 
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ns 
between 
depot 
medroxyp
rogestero
ne acetate 
and 
combinati
on 
antiretrov
iral 
therapy 
single muscular injection 
of DMPA 150 mg.  
 
15 HIV-positive women 
receiving ART received a 
single muscular injection 
of DMPA 150 mg.    
the first 12 weeks after DMPA administration 
was 101.9 (30.2) in the ART group and 99.1 
(21.6) in the non-ART group, with a ratio of 1.01 
(95% CI 0.85–1.20). 
 
Mean Cmax (maximum concentration) was 2.6 for 
the intervention group and 2.5 for the control 
group (ratio 1.01, 95% CI 0.84–1.22). 
 (Nanda 
et al., 
2013) 
Nevirapin
e-based 
antiretrov
iral 
therapy 
does not 
reduce 
oral 
contracep
tive 
effectiven
ess: 
196 women taking 
nevirapine-containing 
ART treated with 
combined oral 
contraceptives  
 
206 HIV- positive 
women not yet eligible 
for ART as a control 
group treated with 
combined oral 
contraceptives.  
In the ART group, 43 of 168 (26%) ovulated in 
cycle 1, 30 of 163 (18%) in cycle 2, and 18 of 
163 (11%) in both cycles. In the control group, 
26 of 168 (16%) ovulated in cycle 1, 31 of 165 
(19%) in cycle 2, and 20 of 165 (12%) in both 
cycles. Unadjusted odds ratio 1.36 (95% 
confidence interval 0.85-2.18).  
 
Pregnancy rates 10.0 per 100-women-years in 
the ART group and 10.1 per 100-women-years 
in the non-ART group (no statistical 
significance).  
(Patel et 
al., 
2015) 
Pregnanc
y rates in 
HIV-
positive 
women 
using 
contracep
tives and 
efavirenz-
based or 
nevirapin
e-based 
antiretrov
iral 
therapy in 
Kenya: a 
retrospec
tive 
cohort 
study 
Women were 
administered Nevirapine 
or Efavirenz based ART, 
with co-administration 
of implants, DMPA or 
combined oral 
contraceptives.  
For women using implants, adjusted pregnancy 
incidence was 1.1 per 100 person-years (95% CI 
0.72-1.5) for nevirapine-based ART users and 
3.3 per 100 person-years (1.8-4.8) for efavirenz-
based ART users (adjusted incidence rate ratio 
[IRR] 3.0, 95% CI 1.3-4.6).  
 
Women using depot medroxyprogesterone 
acetate (DMPA) experienced adjusted pregnancy 
incidence was 4.5 per 100 person-years (95% CI 
3.7-5.2) for nevirapine-based ART users and 5.4 
per 100 person-years (4.0-6.8) for efavirenz-
based ART users (adjusted IRR 1.2, 95% CI 0.91-
1.5). 
 
Women using combined oral contraceptive 
methods had 3.1-4.1 higher rates of pregnancy 
than did those using implants, with 1.6-2.8 
higher rates in women using efavirenz-based 
ART 
(Polis et Effect of 418 female Ugandan Composite virologic failure rates 12 months 
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al., 
2012) 
injectable 
contracep
tive use 
on 
response 
to 
antiretrov
iral 
therapy 
among 
women in 
Rakai, 
Uganda 
ART initiators to 
examine the effect of 
injectable contraceptive 
after initiation were similar to women not using 
injectable contraceptives at ART initiation (11% 
vs. 12%, p=0.99).  
 
 
(Pyra et 
al., 
2015) 
Effectiven
ess of 
hormonal 
contracep
tion in 
HIV-
infected 
women 
using 
antiretrov
iral 
therapy: 
5153 HIV-infected 
women followed 
prospectively to 
compare incident 
pregnancy rates by 
contraceptive method 
(implant, injectable, oral 
or none) and ART use. 
 
aHR= adjusted hazard 
ratio 
Women not using any contraception: pregnancy 
incidence rates were 13.2 and 22.5 per 100 
women-years for those on and not on ART, 
respectively.  
 
Women using implants: [aHR 0.06, 95% 
confidence interval (95% CI) 0.01-0.45] and not 
on ART (aHR 0.05, 95% CI 0.02-0.11).  
Pregnancy incidence rate was Less than 1.5 per 
100 person-years among those both on and not 
on ART versus 1.4 for those not using ART. 
 
Women using Injectable (aHR 0.18 on ART and 
aHR 0.20 not on ART). Pregnancy incidence rate 
was 3.3 per 100 person-years among those both 
on and not on ART versus 5.3 for those not using 
ART. 
 
Women using oral contraceptives (aHR 0.37 on 
ART and aHR 0.36 not on ART) also reduced 
pregnancy risk, though by lesser degrees. 
Pregnancy incidence rates were 6.2 per 100 
person-years among those both on and not on 
ART versus 11.1 for those not using ART. 
 
 
 
(Stuart 
et al., 
2011) 
Combined 
Oral 
Contracep
tives and 
Antiretro
Nine women enrolled, 3 
in each group. 
 
The women in group 1 
(HIV positive on ARVs) 
N/A 
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viral 
PK/PD in 
Malawian 
Women: 
Pharmaco
kinetics 
and 
Pharmaco
dynamics 
of a 
Combined 
Oral 
Contracep
tive and a 
Generic 
Combined 
Formulati
on 
Antiretro
viral in 
Malawi: 
had been on ARVs for 
121 days before starting 
COCs. 
 
The women in group 2 
had HIV, but did not use 
ARVs.  
 
The women in Group 3 
were HIV negative 
women.  
 
Measures were reported in 
Graphic form. 
(Watts 
et al., 
2008) 
Safety 
and 
tolerabilit
y of depot 
medroxyp
rogestero
ne acetate 
among 
HIV-
infected 
women 
on 
antiretrov
iral 
therapy: 
ACTG 
A5093 
HIV-positive women on 
ART or no ART were 
administered DMPA 150 
mg intramuscularly and 
evaluated for 12 weeks 
for adverse events, 
changes in CD4+ count 
and HIV RNA levels, and 
ovulation 
 
(White
man et 
al., 
2016) 
Associatio
ns of 
hormonal 
contracep
tive use 
with 
measures 
HIV-positive female 
participants were 
administered: combined 
oral contraceptives 
(COCs), depot-
medroxyprogesterone 
acetate (DMPA), a 
Current use of COCs [adjusted hazard ratio 
(aHR) 0.91, 95% confidence interval (CI) 0.56–
1.48] nor DMPA (aHR 1.28, 95% CI 0.71–2.31) 
was associated with a statistically significant 
increase risk for disease progression. 
 
Among participants using ART at enrollment 
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of HIV 
disease 
progressi
on and 
antiretrov
iral 
therapy 
effectiven
ess 
copper intrauterine 
device (IUD) or 
condoms.  
 
Among participants not 
using ART at enrollment, 
multivariate Cox 
regression was used to 
assess the association 
between current 
contraceptive use and 
disease progression 
(CD4 decline to <350 
cells/mm3, ART 
initiation or death).  
(n=77), we found no statistically significant 
differences in the predicted mean changes in 
CD4 cell count comparing current use of COCs 
(p=.1) or DMPA (p=.3) with nonhormonal 
methods. 
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Discussion 
 
Ten of the articles in the systematic review showed no relevant associations 
between the use of both hormonal contraception and antiretroviral therapy among HIV-
positive women. However, two of the articles showed differences in hormonal blood levels 
or pregnancy risk. The purpose of this study was to address the research question ““Does 
the use of antiretroviral therapy or hormonal contraceptives alter the efficacy of either 
drug when used concurrently in HIV-positive women?” The secondary research question 
addressed disease progression with co-administration. While some studies assessed the 
effectiveness of specific antiretrovirals, such as Efavirenz or Nevirapine, which are both 
NNRTIs, most of the studies used a combination method of antiretrovirals, which is most 
commonly practiced among HIV-positive women. 
Efavirenz, a NNRTI, was associated with higher progesterone levels in a study 
conducted by Landolt and associates (Landolt et al., 2013). Efavirenz based ART is the first-
line therapy recommended by the WHO in resource limiting countries (Patel et al., 2015). 
Those using Efavirenz and combined oral contraceptives experienced higher progesterone 
levels compared using other forms of birth control. These higher progesterone levels may 
indicate ovulation and further confirm the notion that co-administration alters the efficacy 
of either drug. This finding may also indicate less uptake of hormonal contraception. 
Additionally, some women experienced higher pregnancy rates while receiving co-
administration of antiretrovirals and DMPA, compared to other forms of contraception 
such as the IUD (Patel et al., 2015). It is important to note that the results of this study may 
not be due to the use of Efavirenz. The results may be a reflection of the real world efficacy 
of hormonal contraceptives versus other birth control methods such as implants, as 
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implants are among the most effective contraception methods available today (Patel et al., 
2015). Among the general population, DMPA and combined oral contraceptives are more 
user dependent than implants, which may explain the effectiveness of the drugs (Patel et 
al., 2015). The results of these studies show that the IUD may be a safer option for women 
looking to avoid ovulation and minimize disease progression.  
The studies addressing disease transmission showed that co-administration of the 
do not increase the risk of disease transmission. No significant changes in HIV RNA or CD4+ 
cell counts were observed in women receiving hormonal contraception versus women not 
receiving hormonal contraception (Watts et al., 2008). This was observed with both DMPA 
and pill users. Additionally, Day and associates detailed HIV-1 RNA shedding in HIV 
positive women engaging in ART and hormonal contraceptive practices versus those not 
receiving hormonal contraception (Day et al., 2014). Researchers found that those using 
hormonal contraception (DMPA) did not experience increased cervical and plasma HIV-1 
RNA shedding. These findings indicate DMPA is unlikely to increase infectivity in HIV-
positive women who use antiretroviral therapy (Day et al., 2014). In regards to a woman’s 
own health, hormonal contraception seems to be well tolerated among antiretroviral users. 
Additionally, concurrent use does not seem to increase the risk of infectivity.   
 This systematic review had limitations in that there is limited data on the potential 
interactions of antiretroviral and hormonal contraception. The study only used databases 
made available by Georgia State University, which limited the search of articles that met the 
inclusion criteria. Additional databases were not used in this systematic review because 
these databases required payment to garner access. Also, in some of the studies, the sample 
sizes were relatively small. Therefore, without additional studies in the subject area, it may 
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be problematic to generalize the results of the studies to similar populations. Also, there 
were additional studies that assessed birth control in HIV-positive women, but these 
studies did not co-administer antiretrovirals and hormonal contraception.  
 
Conclusion 
 It is important to for HIV-positive women to have safe and effective means of 
contraception. Because the proportion of AIDS cases continues to rise globally among 
women, vertical transmission is a topic of concern, especially among women in 
childbearing age (Watts et al., 2008).  Women should also be provided options for birth 
control as some women may not want children, have health problems that will make 
pregnancy risky, or want to be engaged in their own family planning.  
Although there are concerns about the metabolism of hormonal contraception and 
antiretroviral therapy along the cytochrome P450 pathway, published data has shown 
minimal interactions when the drugs are co-administered. Further research needs to be 
conducted in order to evaluate the efficacy of co-administration of hormonal contraception 
and HIV. Because data is currently limited on the potential interactions among hormonal 
contraception and antiretroviral therapy, options for safe and effective contraceptive 
options are also limited among HIV-positive women. The understanding and use of 
antiretroviral therapy has grown significantly over the past 30 years and co-administration 
with hormonal contraception should be further examined because it is important for HIV-
positive women to have control over their health and fertility.  Certain antiretroviral drugs 
such as Efavirenz has shown to have negative effects on the body when co-administered 
with hormonal contraception. This may indicate that more research should be done on 
specific NNRTIs and PIs as it relates to concurrent use.  The results of this systematic 
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review indicate that women can use hormonal contraception and antiretroviral therapy 
concurrently without concerns about disease transmission and disease progression. 
However, there may be a warrant for concern in regards to pregnancy risk and women 
should use more effective forms of contraception such as the IUD. Additionally, women 
using NNRTIs or PIs should be advised of the risks associated with concurrent use, and are 
provided with other options as needed.  
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